MX2021009769A - Produccion de composiciones que comprenden dos o mas anticuerpos. - Google Patents

Produccion de composiciones que comprenden dos o mas anticuerpos.

Info

Publication number
MX2021009769A
MX2021009769A MX2021009769A MX2021009769A MX2021009769A MX 2021009769 A MX2021009769 A MX 2021009769A MX 2021009769 A MX2021009769 A MX 2021009769A MX 2021009769 A MX2021009769 A MX 2021009769A MX 2021009769 A MX2021009769 A MX 2021009769A
Authority
MX
Mexico
Prior art keywords
antibodies
iex
relates
retention times
compositions
Prior art date
Application number
MX2021009769A
Other languages
English (en)
Inventor
Alexander Berthold Hendrik Bakker
Robert Paul Doornbos
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MX2021009769A publication Critical patent/MX2021009769A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Abstract

La invención se refiere a medios y métodos para producir por lo menos dos anticuerpos. Los métodos pueden incluir proporcionar a las células ácido nucleico que codifica los anticuerpos; cultivar las células; recolectar los anticuerpos del cultivo; y separar los anticuerpos producidos de los semianticuerpos por cromatografía de intercambio iónico (IEX). En algunas modalidades, los anticuerpos exhiben tiempos de retención de IEX que se desvían en 10 % o menos del promedio de los tiempos de retención de los anticuerpos individuales en las condiciones de IEX usadas. La invención también se refiere a composiciones de anticuerpos así producidos. En algunos aspectos, la invención se refiere a composiciones que comprenden 2-10 anticuerpos recombinantes caracterizados porque los tiempos de retención de IEX de por lo menos dos de los anticuerpos se desvían en 10 % o menos del promedio de los tiempos de retención de los anticuerpos individuales en las condiciones de IEX. Además se refiere a composiciones que comprenden 2-10 anticuerpos recombinantes caracterizados porque el pI de por lo menos dos de los anticuerpos difiere por 0.4 unidades o menos del pI promedio de los por lo menos dos anticuerpos.
MX2021009769A 2019-02-14 2020-02-13 Produccion de composiciones que comprenden dos o mas anticuerpos. MX2021009769A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19157286 2019-02-14
EP19178542 2019-06-05
PCT/NL2020/050080 WO2020167122A1 (en) 2019-02-14 2020-02-13 Producing compositions comprising two or more antibodies.

Publications (1)

Publication Number Publication Date
MX2021009769A true MX2021009769A (es) 2021-09-08

Family

ID=69771002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009769A MX2021009769A (es) 2019-02-14 2020-02-13 Produccion de composiciones que comprenden dos o mas anticuerpos.

Country Status (12)

Country Link
US (1) US20220127375A1 (es)
EP (1) EP3924377A1 (es)
JP (2) JP7375027B2 (es)
KR (1) KR20210126699A (es)
AU (1) AU2020221649A1 (es)
CA (1) CA3130246A1 (es)
IL (1) IL285489A (es)
MA (1) MA54943A (es)
MX (1) MX2021009769A (es)
SG (1) SG11202108840XA (es)
TW (1) TW202045132A (es)
WO (1) WO2020167122A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11732043B2 (en) * 2017-07-06 2023-08-22 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
JP2024500747A (ja) * 2020-12-18 2024-01-10 キニクサ ファーマシューティカルズ， リミテッド タンパク質組成物ならびにそれを産生及び使用するための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856324A (zh) * 2002-09-17 2006-11-01 Gtc生物治疗学公司 缺乏重链间二硫键的免疫球蛋白分子的分离
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
CN112481300A (zh) 2008-06-27 2021-03-12 莫鲁斯股份有限公司 产生抗体的非人哺乳动物
US8597652B2 (en) 2009-03-20 2013-12-03 Genentech, Inc. Multispecific anti-HER antibodies
JP6087054B2 (ja) * 2009-12-25 2017-03-01 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
JP6393255B2 (ja) 2012-04-20 2018-09-19 メルス ナムローゼ フェンノートシャップ ヘテロ二量体のＩｇＧ様分子を生産する方法、ヘテロ二量体のＩｇＧ様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物
CN105473612A (zh) * 2013-08-19 2016-04-06 豪夫迈·罗氏有限公司 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
CA3065447A1 (en) * 2017-06-05 2018-12-13 Janssen Biotech, Inc. Methods of engineering surface charge for bispecific antibody production

Also Published As

Publication number Publication date
JP2023171492A (ja) 2023-12-01
CA3130246A1 (en) 2020-08-20
SG11202108840XA (en) 2021-09-29
WO2020167122A1 (en) 2020-08-20
AU2020221649A1 (en) 2021-09-02
JP7375027B2 (ja) 2023-11-07
MA54943A (fr) 2021-12-22
JP2022520972A (ja) 2022-04-04
IL285489A (en) 2021-09-30
TW202045132A (zh) 2020-12-16
EP3924377A1 (en) 2021-12-22
KR20210126699A (ko) 2021-10-20
US20220127375A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
US20210085725A1 (en) Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
Kuhn et al. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis
US20170121685A1 (en) Mesenchymal stem cell-derived exosomes and their uses
MX2021009769A (es) Produccion de composiciones que comprenden dos o mas anticuerpos.
Ulrich et al. Human placenta-derived CD146-positive mesenchymal stromal cells display a distinct osteogenic differentiation potential
Stephens et al. IL‐9 is a Th17‐derived cytokine that limits pathogenic activity in organ‐specific autoimmune disease
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
WO2011091350A3 (en) Methods & compositions for improving protein production
MX2022001977A (es) Poblaciones de celulas t gamma delta t ex vivo.
PE20221791A1 (es) Composiciones de proteina anti-vegf y metodos para producir la misma
MX2020010724A (es) Metodos para preparar composiciones proteicas estables.
BR112021024848A2 (pt) Métodos de purificação de anticorpos e composições dos mesmos
MX2022006390A (es) Transducción de car y edición de genes mediante crispr combinadas de células nk a gran escala.
JOP20210309A1 (ar) جزيئات ربط بـ cd19 واستخدامتها
MX2021012041A (es) Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas.
MX2021009967A (es) Metodos para producir celulas t autologas utiles para tratar cancer y composiciones de las mismas.
Liu et al. TNF-α induced the enhanced apoptosis of mesenchymal stem cells in ankylosing spondylitis by overexpressing TRAIL-R2
Lefèvre et al. Kidney inflammaging is promoted by CCR2+ macrophages and tissue-derived micro-environmental factors
WO2022162518A3 (en) Psma binding proteins and uses thereof
Saeed et al. Bone Marrow Stromal Cell (BMSC) and skeletal aging: role of telomerase enzyme.
WO2006042105A3 (en) Promotion of cell migration and axon regeneration in the cns
EP3985106A1 (en) Conditioned regulatory t cell population with enhanced therapeutic potential, method for obtaining of regulatory t cell population and the medical use of regulatory t cell population
WO2019227106A9 (en) Tumor-specific neoantigens and methods of using the same
Maijenburg et al. Cell cycle and tissue of origin contribute to the migratory behaviour of human fetal and adult mesenchymal stromal cells
EA202191940A1 (ru) Получение композиций, содержащих два или более антитела